Medical monitoring project surveillance summary: behavioral and clinical characteristics of persons receiving HIV care in Georgia, 2009-2013

Medical Monitoring Project Surveillance Summary
Behavioral and Clinical Characteristics of Persons Receiving HIV Care in Georgia, 20092013
HIV/AIDS Epidemiology Section Epidemiology Program Division of Health Protection Georgia Department of Public Health

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 1

This Medical Monitoring Project Surveillance Summary, Georgia 2009-2013 is published by the Georgia Department of Public Health (DPH), HIV/AIDS Epidemiology Section, Epidemiology Program, 2 Peachtree Street NW, Atlanta, Georgia 30303.
The Medical Monitoring Project Surveillance Summary, Georgia 2009-2013 is not copyrighted and may be used and reproduced without permission. Citation of the source is, however, appreciated.
SUGGESTED CITATION: Georgia Department of Public Health, HIV/AIDS Epidemiology Section Medical Monitoring Project Surveillance Summary: Behavioral and Clinical Characteristics of Persons Receiving HIV Care in Georgia, 2009-2013, https://dph.georgia.gov/data-fact-sheet-summaris, Published March 2016, [Accessed: date]
ACKNOWLEDGEMENTS: Publication of this report was made possible with the contributions of the Georgia MMP Team, assistance from the participating facilities, and the cooperation of participating patients.
Georgia MMP Team: Natalie Spears, Heather Brightharp, Melissa Gousse, Timothy Lockhart, David Maggio and Shaunta Rutherford.
The report was prepared using code provided by CDC to replicate the national report, and the text is based on the national report: Centers for Disease Control and Prevention. Behavioral and Clinical Characteristics of Persons Receiving Medical Care for HIV Infection--Medical Monitoring Project, United States, 2011. HIV Surveillance Special Report 10. http://www.cdc.gov/hiv/library/reports/surveillance/#special. Published January 2015. Accessed 2/24/2016.
This report was prepared by the following staff of the Georgia Department of Public Health: David Maggio, MPH, Jane Kelly, MD, Pascale Wortley, MD, MPH; Cherie Drenzek, DVM, MS.

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 2

Table of Contents
Background........................................................................................................................................................................5
Highlights ..................................................................................................................................................................... 5
Technical notes.................................................................................................................................................................7
Table 1. Facility and patient response rates by project year................................................................................... 9
Table 2. Characteristics of patients.................................................................................................................... 10
Table 3. Stage of disease, CD4 counts, and viral suppression during the 12 months before interview .......... 14
Table 4. CD4 and viral load monitoring and prescription of antiretroviral therapy, Pneumocystis pneumonia (PCP) prophylaxis during the 12 months before interview ................................................................................ 16
Table 5. Clinical services during the 12 months before the interview ...................................................................18
Table 6. Sexually transmitted disease testing during the 12 months before the interview, by sexual activity .............................................................................................................................................................................19
Table 7. Emergency department or urgent care clinic use and hospital admission during the 12 months before the interview ......................................................................................................................................................21
Table 8. Antiretroviral therapy use, payment source, and adherence ..................................................................22
Table 9. Beliefs among patients currently taking antiretroviral medications ......................................................26
Table 10. Reasons for missed antiretroviral therapy dose, among those missing a dose during the 12 months before the interview .................................................................................................................................27
Table 11. Depression during the 12 months before the interview.........................................................................29
Table 12. Cigarette smoking.........................................................................................................................................30
Table 13. Alcohol use during the 12 months before the interview.........................................................................31 . Table 14. Non injection drug use during the 12 months before the interview.....................................................33
Table 15. Injection drug use during the 12 months before the interview.............................................................36
Table 16. Gynecological history and reproductive health among women............................................................38

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 3

Table 17. Sexual orientation and sexual activity during the 12 months before the interview...........................39
Table 18. Sexual risk behaviors during the 12 months before the interview among men who have sex with men, by type of partner.......................................................................................................................................41
Table 19. Sexual risk behaviors during the 12 months before the interview among men who have sex with women, by type of partner ................................................................................................................................43
Table 20. Sexual risk behaviors during the 12 months before the interview among women who have sex with men, by type of partner.......................................................................................................................................45
Table 21. Met and unmet needs for ancillary services during the 12 months before the interview................47
Table 22. Prevention services received during the 12 months before the interview......................................... 50
Definitions...................................................................................................................................................................... 52

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 4

Background
As of December 31, 2013, an estimated 51,510 persons in Georgia were living with diagnosed HIV infection and there were 2,661 new HIV diagnoses in 2013 [1]. Supplemental information on care seeking, health care use, use of ancillary services, and other behaviors adds to the information collected through case surveillance activities. Georgia is one of 23 project areas funded by CDC to conduct the Medical Monitoring Project (MMP). The MMP is a cross-sectional, nationally representative, complex sample survey that assesses the clinical and behavioral characteristics of HIV-infected adults who are receiving outpatient medical care in the United States and Puerto Rico [2,3].
The Georgia MMP sample was selected in 2 consecutive stages: (1) outpatient facilities providing HIV care, and (2) HIV-infected adults aged 18 years who made at least 1 medical care visit to a participating facility during January April of each project year. This report presents unweighted sample sizes and weighted prevalence estimates with 95% confidence intervals for selected characteristics for the 2009-2013 Georgia MMP Project years. National MMP data from the 2011 survey are included in the tables for comparison. The period referenced is the 12 months before the patient interview unless otherwise noted. Statistical software (SAS, version 9.3) was used for analysis of weighted data [4]. Weighted prevalence estimates and 95% confidence intervals are not reported for variables with <5 responses or a coefficient of variation of 30%. For more information on methods, see Technical notes, page 7.
Highlights
Sociodemographic Characteristics
An estimated 71% of patients were male, 28% were female, and 1% were transgender (Table 2). Nearly half (49%) of patients identified themselves as heterosexual, or straight; 40% as homosexual, gay, or lesbian; and 11% as bisexual. An estimated 67% were black or

African American, 22% were white, and 5% were Hispanic or Latino. More than two thirds (71%) were aged at least 40 years, and 52% had received an HIV diagnosis at least 10 years earlier. More than half (56%) had more than a high school education, and 95% were born in the United States. The estimated prevalence of homelessness in the previous 12 months was 9%. An estimated 93% had health insurance or coverage for antiretroviral therapy (ART) medications: 27% had Medicaid, 34% had coverage through the Ryan White HIV/AIDS Program, 32% had private health insurance, and 26% had Medicare. An estimated 41% had household incomes at or below the federal poverty threshold.
Clinical Characteristics
According to the CDC stage of disease classification for HIV infection, an estimated 71% of patients had stage 3 (AIDS) disease (Table 3). An estimated 16% of patients had a mean CD4 T-lymphocyte (CD4) count of 0199 cells/L in the previous 12 months. The estimated geometric mean CD4 count among all patients in the previous 12 months was 482 cells/L, and the median CD4 count was 440 cells/L (range, 3-1,821) (data not shown in table). Nearly 77% of patients had an undetectable (<200 copies/ml) viral load at the most recent measurement.
Use of Health Care Services
An estimated 71% of patients had at least 3 CD4 or HIV viral load tests documented in the medical record (Table 4). As recommended by guidelines, most patients had at least 1 viral load test in each 6-month period (76%) and at least one CD4 test annually (94%). Overall, an estimated 93% of patients had an ART prescription documented in the medical record. Of patients who met the clinical criteria for Pneumocystis pneumonia (PCP) prophylaxis, 79% had a prescription for PCP prophylaxis documented in the medical record. Nearly 100% of patients received most of their HIV medical care at a single place (e.g., a physician's office or a clinic) (Table 5). Patients' estimated travel time to their usual HIV

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 5

care provider averaged 32 minutes. In total, 6% of patients participated in an HIV clinical trial. Among sexually active patients, an estimated 39% were tested for gonorrhea, 39% for chlamydia, 57% for syphilis, and 33% for all 3 sexually transmitted diseases (STDs) (Table 6). An estimated 7% of patients were seen in an emergency department or an urgent care center at least 1 time (Table 7). An estimated 3% of patients were admitted to a hospital for an HIV-related illness at least 1 time.
Self-reported Antiretroviral Medication Use and Adherence
An estimated 92% of patients were currently taking ART (Table 8). Among the estimated 3% of patients without a history of ART use, 81% had never taken ART because a physician advised a delay in treatment; two or fewer reported as reasons that that medications were unnecessary because they felt healthy or believed their HIV laboratory test results (e.g., CD4 count and HIV viral load) were good; money or insurance issues; and use of alternative medicines. Patients' ART medications were most commonly paid for by the AIDS Drug Assistance Program (39%), Medicaid (20%), private health insurance (23%), or Medicare (19%).
Estimated adherence to dose, schedule, and special instructions for taking ART during the past 3 days was 86%, 76%, and 74%, respectively. Among patients currently taking ART, 73% had never been troubled by ART side effects; 15% had rarely been troubled. Among patients currently taking ART, an estimated 96% were "very" or "extremely" sure that they could take all of their medication as directed, and 88% believed that their medication would have a positive effect on their health (Table 9). Among the estimated 64% of patients who were currently taking ART and ever missed a dose (Table 8), 30% most recently missed a dose because of a change in daily routine, and 24% most recently missed a dose because they forgot to take it (Table 10).
Depression and Substance Use
The estimated prevalence of major or other depression based on the DSM-IV criteria was 21%, including 9%

with major depression (Table 11). Based on the total PHQ-8 symptom score (see the appendix), an estimated 20% of patients had current moderate or severe depression.
The estimated prevalence of smoking in the previous 12 months was 35%: 29% of patients smoked daily, and 4% weekly (Table 12). The estimated prevalence of alcohol use in the previous 12 months was 70%: 6% of patients drank alcohol daily, 20% weekly, 14% monthly, and 31% less than monthly (Table 13). Nearly 30% of patients drank alcohol before or during sex. An estimated 53% of patients drank alcohol during the past 30 days. Among patients who drank alcohol during the past 30 days, the estimated typical average daily consumption was 2.5 drinks. An estimated 15% of patients engaged in binge drinking during the past 30 days. Among patients who drank alcohol in the past 30 days, the estimated mean number of binge-drinking days was 0.8.
An estimated 22% of patients used non-injection drugs for nonmedical purposes, and 12% used non-injection drugs before or during sex (Table 14). In total, an estimated 20% used marijuana, 4% used cocaine, 2% used poppers (amyl nitrite), and 2% used methamphetamine. An estimated 1% of patients used injection drugs for nonmedical purposes (n=9) (Table 15).
Gynecologic and Reproductive Health
An estimated 9% of female patients received HIV care at an obstetrics and gynecology clinic, and 84% received a Papanicolaou (Pap) test (Table 16). An estimated 21% of female patients had been pregnant at least once since testing positive for HIV infection; of these, 77% gave birth to 1 or more children after learning their HIV status.
Sexual Behavior
An estimated 49% of patients were gay, bisexual, and other men who have sex with men (collectively referred to as MSM); 22% were men who exclusively have sex with women; 28% were women who have sex with men; fewer than 1% were women who exclusively have

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 6

sex with women; and 1% were transgender (Table 17). An estimated 64% of patients were sexually active, including 78% of MSM, 44% of men who have sex with women, 51% of women who have sex with men, and 43% of women who have sex with women.. Among all patients, 22% had engaged in unprotected sex, and 11% had engaged in unprotected sex with a partner of negative or unknown HIV status.
Among MSM, 28% had engaged in unprotected anal intercourse, and 12% had engaged in unprotected anal intercourse with a partner of negative or unknown HIV status (Table 18). Among men who have sex with women, 6% had engaged in unprotected vaginal intercourse, and 3% had engaged in unprotected vaginal intercourse with a partner of negative or unknown HIV status (Table 19). Among women who have sex with men, 23% had engaged in unprotected vaginal intercourse, and 16% had engaged in unprotected vaginal intercourse with a partner of negative or unknown HIV status (Table 20).
Met and Unmet Need for Ancillary Services
An estimated 55% of patients received dental care, 46% received HIV case management services, 45% received medicine through the AIDS Drug Assistance Program, and 45% received counseling about how to prevent the transmission of HIV (Table 21). An estimated 29% of patients had unmet needs for dental care; 17% for public benefits, such as Social Security Income or Social Security Disability Insurance; 10% for transportation assistance; 9% for HIV peer group support; 10% for shelter or housing services; 9% for meal or food services; 8% for HIV case management services; and 6% for mental health services.
Prevention Activities
An estimated 47% of patients received counseling from a physician, nurse, or other health care worker about HIV and STD prevention; 31% had a one-on-one conversation with an outreach worker, a counselor, or a prevention program worker about prevention; and 15% participated in a small-group session (excluding discussions with friends) to discuss the prevention of

HIV and other STDs (Table 22). An estimated 51% of patients received free condoms from various organizations; of these, 85% received free condoms from a general health clinic, 11% from an HIV/AIDSfocused community-based organization, 8% from a social venue (i.e., bar, club, bathhouse, gym, bookstore), 3% from an STD clinic, 4% from a special event, <1% from an outreach organization focused on injection drug use (excluding needle exchange programs), and <1% from a family planning clinic.
Technical Notes
Population inference
For each Georgia MMP data collection cycle, the population of inference is HIV-infected adults (aged 18 years and older) who received care from known providers of outpatient HIV medical care in Georgia during the population definition period (PDP). For all project areas, the PDP is a predefined period during which HIV-infected persons must have received care in a sampled facility in order to be sampled for participation in MMP. The PDP for each year 2009-2013 was January 1 through April 30. CDC selected this approach because published research suggests that of all HIV-infected persons in medical care, 88% had visited their HIV medical care provider at least once during the first 4 months of the specified calendar year [5].
Data collection
Patients were enrolled by either MMP staff or health facility staff. The enrollment strategy depended on clinic needs, project area needs, local institutional review board requirements, and the number of patients sampled from a given facility. For enrollment by MMP staff, facilities provided local MMP staff with contact information for patients. For enrollment by HIV medical care providers, selected patients were initially contacted by their health care providers--in person, by telephone, or by mail--and then were contacted by MMP staff. The participant eligibility criteria were: diagnosis of HIV infection, age of 18 years at the

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 7

beginning of the 4-month period when patients were eligible for selection (PDP), no previous participation in MMP during the current data collection cycle, and receipt of medical care at the sampled facility during the PDP. A trained interviewer conducted a computerassisted personal interview. Persons who agreed to participate were interviewed in a private location (e.g., at home or in a clinic) or over the telephone. Participants were reimbursed approximately $50 in cash or the equivalent for participation. After the interview, medical records were abstracted by MMP staff, using an electronic application provided by CDC.
Facility and patient response rates
Facility and patient response rates by project year are shown in Table 1. The number of sampled facilities ranged from 20 to 38 per year, and 400 patients were sampled from the participating facilities each year. Over this 5 year period, 795 patients completed the standard questionnaire, and their medical records were abstracted. The facility and patient response rates for each project year (2009-2013) are shown in Table 1.
References
1. Georgia Department of Public Health, HIV/AIDS Epidemiology Section HIV Surveillance Summary, Georgia 2013, https://dph.georgia.gov/data-fact-sheetsummaris, Published May 2015, [Accessed: 1/12/2016]
2. CDC Medical Monitoring Project website http://www.cdc.gov/hiv/statistics/systems/mmp/ [Accessed 1/12/2016]
3. McNaghten AD, Wolfe MI, Onorato I, et al. Improving the representativeness of behavioral and clinical surveillance for persons with HIV in the United States: the rationale for developing a population-based approach. PLoS One 2007;2 (6):e550.
4. SAS Institute Inc. SAS version 9.3. Cary, NC: SAS Institute; 2011.

5. Sullivan PS, Juhasz M, McNaghten AD, et al. Time to first annual HIV care visit and associated factors for patients in care for HIV infection in 10 US cities. AIDS Care 2011;23(10):1314-1320.

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 8

Table 1. Facility and Patient Response Rates by Project Year

2009 2010 2011 2012 2013

Facilities Sampled 38 38 20 20 30

Response rate 57% 45% 75% 75% 70%

Patients

Sampled Response rate

400

48%

400

39%

400

31%

400

46%

400

48%

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 9

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 10

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 11

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 12

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 13

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 14

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 15

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 16

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 17

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 18

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 19

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 20

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 21

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 22

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 23

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 24

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 25

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 26

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 27

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 28

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 29

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 30

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 31

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 32

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 33

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 34

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 35

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 36

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 37

Excluded are choices with fewer than 5 responses, values with a coefficient of variation greater than .30, "don't know" responses, and skipped (missing) responses. a Numbers are unweighted. b Percentages are weighted percentages. c CIs incorporate weighted percentages. d Among women who had been pregnant since HIV diagnosis. e Among women who had been pregnant during past 12 months
Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 38

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 39

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 40

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 41

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 42

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 43

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 44

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 45

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 46

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 47

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 48

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 49

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 50

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 51

DEFINITIONS
Sociodemographic Characteristics
Gender: Categories were male, female, and transgender. Participants were classified as transgender if reported sex at birth and current gender as reported by the participant were not the same or if the participant answered "transgender" to the interview question regarding self-identified gender.
Health insurance or other coverage for ART medications: Participants were asked whether they had health insurance and whether they had other coverage for ART medications during the 12 months before interview. Responses to these questions were combined and categorized as private health insurance, Medicaid, Medicare, Ryan White HIV/AIDS Program, Tricare/CHAMPUS and Veterans Administration coverage, insurance classified as other public health insurance, and unknown insurance. Participants could select >1 response for health insurance or other coverage for ART medications.
Federal poverty guidelines: Participants were asked about their combined monthly or yearly household income (in US$) from all sources during the 12 months before interview. The number of persons meeting the current federal poverty threshold was determined by using the U.S. Department of Health and Human Services poverty guidelines that corresponded to the calendar year for which income was asked. These guidelines are issued yearly for the 48 contiguous U.S. states and Washington, D.C., and are one indicator used for determining eligibility for many federal and state programs. The 2010 guidelines were used for participants interviewed in 2011, and the 2011 guidelines were used for persons interviewed in 2012. Because the poverty guidelines are not defined for the territory of Puerto Rico, the guidelines for the contiguous states and Washington, D.C., were used for this jurisdiction. Participants were asked to specify the range of their income. If the participant's income range and household size resulted in an ambiguous

determination of poverty level, the participant's household income was assumed to be the midpoint of the income range.
Clinical Characteristics
CDC stage of disease classification for HIV infection: Defined according to CDC's 2008 revised surveillance case definition for HIV infection. To determine the stage of HIV infection, medical record data from the time since HIV diagnosis and the 12 months before interview were abstracted
Use of Health Care Services
HIV medical care: Participants were asked whether, during the 12 months before the interview, they had a usual source of primary HIV medical care. HIV medical care was defined as CD4 count or viral load testing and prescribing ART in the context of treating and managing a patient's HIV disease on an outpatient basis.
ART prescription: Defined as a prescription in the medical record, during the 12 months before the interview, of any of the following medications: abacavir, amprenavir, atazanavir, darunavir, delavirdine, didanosine, efavirenz, emtricitabine, enfuvirtide, etravirine, fosamprenavir, indinavir, lamivudine, lopinavir/ritonavir, maraviroc, nelfinavir, nevirapine, raltegravir, ritonavir, saquinavir, stavudine, tenofovir, tipranavir, zalcitabine, or zidovudine.
Pneumocystis pneumonia (PCP) prophylaxis: Defined as documentation in the medical record, during the 12 months before the interview, that prophylaxis for PCP was prescribed or that regimens typically given as PCP prophylaxis were prescribed (trimethoprimsulfamethoxazole, dapsone with or without pyrimethamine and leucovorin, aerosolized pentamidine, and atovaquone) among persons with a CD4 count of <200 cells/L during the 12 months before the interview.
Neisseria gonorrhoeae testing: Defined as documentation in the medical record, during the 12 months before the interview, of a result from culture,

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 52

gram stain, nucleic acid amplification test (NAAT), or nucleic acid probe.
Chlamydia trachomatis testing: Defined as documentation in the medical record, during the 12 months before the interview, of a result from culture, direct fluorescent antibody (DFA), enzyme immunoassay (EIA) or enzyme-linked immunoassay (ELISA), NAAT, or nucleic acid probe.
Syphilis testing: Defined as documentation in the medical record, during the 12 months before the interview, of a result from non-treponemal syphilis tests (rapid plasma reagin [RPR], Venereal Disease Research Laboratory [VDRL]), treponemal syphilis tests (Treponema pallidum hemagglutination assay [TPHA], T. pallidum particle agglutination [TP-PA], microhemagglutination for antibody to T. pallidum [MHA-TP], fluorescent treponemal antibody absorption [FTA-ABS] tests), or darkfield microscopy.
Influenza vaccination: Participants were asked whether they had received seasonal influenza vaccine during the 12 months before the interview and whether they had received vaccination for H1N1. Participants were considered vaccinated for influenza if they answered yes to either question.
Self-reported Antiretroviral Medication Use and Adherence
ART adherence: Participants were asked about adherence, over the past 3 days, to ART doses, schedules, and special instructions for taking ART. Dose adherence referred to taking a dose or set of pills/spoonfuls/injections of ART medications. Schedule adherence referred to following a specific schedule for ART medication timing, such as "2 times a day" or "every 8 hours." Special instruction adherence referred to following special instructions for ART medication, such as "take with food" or "on an empty stomach."
Depression and Substance Use
Depression: Participants were asked questions from the Patient Health Questionnaire (PHQ-8), an 8-item scale used to measure frequency of depressed mood in

the preceding 2 weeks. The PHQ-8 has the following question: "Over the last 2 weeks, how often have you been bothered by any of the following problems?" The respondent is then asked about the following problems: (1) little interest or pleasure in doing things (anhedonia); (2) feeling down, depressed, or hopeless; (3) trouble falling/staying asleep, or sleeping too much; (4) feeling tired or having little energy; (5) poor appetite or overeating; (6) feeling bad HIV Surveillance Special Report 41 No. 10 about yourself or that you are a failure or have let yourself or your family down; (7) trouble concentrating on things, such as reading the newspaper or watching television; (8) moving or speaking so slowly that other people could have noticed, or being fidgety or restless or moving around a lot more than usual. Response categories were "not at all," "several days," "more than half the days," and "nearly every day." The PHQ-8 responses were scored by using 2 methods. Method 1: an algorithm involving criteria from the Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV), for diagnosing major depression was used to classify adults receiving medical care for HIV infection as having major depression, other depression, or no depression. To meet the criteria for any type of depression, a participant must have experienced a number of symptoms, at least 1 of which was anhedonia or feelings of hopelessness (at least 5 symptoms for major depression, 2 to 4 symptoms for other types of depression) for half the days or nearly every day. Method 2: a score-based method, calculated as the sum of scores from the responses in the scale, was used to determine the presence of current depression of moderate or severe intensity, which was defined as a sum score of 10.
Alcohol use: Participants were asked about alcohol use during the 12 months and 30 days before the interview. A drink was defined as 12 ounces of beer, a 5-ounce glass of wine, or a 1.5-ounce shot of liquor.
Heavy drinking: Defined as an average of >2 drinks per day, or >14 drinks per week, for men and an average of >1 drink per day, or >7 drinks per week, for women.

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 53

Binge drinking: Defined as 5 drinks in one sitting for men and 4 drinks in one sitting for women.
Sexual Behavior
Sexual behavior: Defined as anal intercourse, vaginal intercourse, or oral sex for men who have sex with men, men who have sex with women, and women who have sex with men. Defined as anal intercourse or vaginal intercourse for transgender persons. Defined as any sexual activity for women who have sex with women.
Gender of sex partners and sexual orientation: Men who have sex with men (MSM) were defined as men who reported sex with one or more men in the 12 months before interview, regardless of whether they also reported sex with women, or if no sexual activity was reported, men who self-identified as homosexual, gay, or bisexual. Men who exclusively have sex with women were defined as men who reported sex only with women in the 12 months before interview, or if no sexual activity reported, men who self-identified as heterosexual/straight. Women who have sex with men were defined as women who reported sex with one or more men in the 12 months before interview, regardless of whether they also reported sex with women, or if no sexual activity was reported, women who self-identified as heterosexual/straight or bisexual. Women who exclusively have sex with women were defined as women who reported sex with women only in the 12 months before interview, or if no sexual activity was reported, women who self-identified as homosexual, gay, or lesbian. Transgender persons were defined as previously described. Participants who did not fit into any of the categories above (i.e., were unclassified because they had not engaged in sexual activity during the past year and did not report their sexual orientation) were categorized as other/unclassified. These categories are mutually exclusive (i.e., a participant could not be transgender and be placed in any other category).

were asked about the number of sex partners and whether they considered the partners to be main or casual. A main partner was defined as a person to whom the respondent felt most committed. A casual partner was defined as person to whom the respondent did not feel committed or whom he or she did not know very well.
Unprotected sex: Defined as vaginal or anal intercourse without a condom or condom use for part of the time during a sexual act during the 12 months before the interview.
Unprotected sex with partners of negative or unknown status: The number of HIV-positive partners reported by a participant during the 12 months before the interview was subtracted from HIV Surveillance Special Report 42 No. 10 the total number of partners with whom the participant reported unprotected sex. If the numbers were not equal (i.e., not all partners were HIV-positive), the participant was considered to have had unprotected sex with a partner of negative or unknown HIV status.
Met and Unmet Needs for Ancillary Services
Met need: Defined as an ancillary service (e.g., HIV case management services, dental care, mental health services) received during the 12 months before the interview.
Unmet need: Defined as an ancillary service that the participant reported as needed but not received during the 12 months before the interview.

Main and casual sex partners: Participants reporting sexual activity in the 12 months before the interview

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 54

HIV/AIDS Resources:

Georgia Department of Public Health http://dph.georgia.gov/what-hiv-and-aids

Centers for Disease Control and Prevention http://www.cdc.gov/hiv/

AIDSVu http://aidsvu.org/

Reporting All health care providers diagnosing and/or providing care to a patient with HIV are required by Georgia law (O.C.G.A. 31-12-1) to report HIV infection using the HIV/AIDS Case Report Form. Case report forms should be completed within seven (7) days of diagnosing a patient with HIV and/or AIDS or within seven (7) days of assuming care of an HIV positive patient who is new to the provider, regardless of whether the patient has previously received care elsewhere. Adult and Pediatric case report forms are available at http://dph.georgia.gov/reporting-forms-data-requests For more questions on HIV case reporting in Georgia please contact the HIV Surveillance Coordinator at 1-800-827-9769

Georgia Medical Monitoring Project (MMP) Surveillance Summary, 2009-2013

Page 55

Locations